semaglutide injection fairhope al Flex-Dose 4 mL Injectable 2.5 mg/mL semaglutide injection fairhope al Semaglutide

SURMOUNT-5 showed Mounjaro produces 6.5 percentage points more weight loss on average

In addition, patients who had more extensive resurfacing regained only about 7 pounds and kept more than 80% of their weight loss

The drug is a once-a-week injection that combines two hormones, GLP-1 and GIP, which work in combination to stimulate insulin secretion and reduce appetite

Abildstrm, B.A

Pedersen JS

For currently approved GLP-1 receptor agonists available for weight management in the UK, NICE has established specific eligibility criteria: Semaglutide (Wegovy) NICE TA875 recommends semaglutide for adults with: A body mass index (BMI) of 35 kg/m or above with at least one weight-related comorbidity (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity, prescribed only in specialist weight management services Evidence of previous unsuccessful weight loss attempts through diet, physical activity, and behavioural interventions Treatment is limited to a maximum of 2 years Liraglutide (Saxenda) NICE TA664 recommends liraglutide for adults with: A BMI of 35 kg/m or above (with or without comorbidities), or A BMI of 3034.9 kg/m with at least one weight-related comorbidity Evidence of previous unsuccessful weight loss attempts Treatment is limited to a maximum of 2 years Both medications must be prescribed as part of a specialist weight management service providing multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions